Brussels & Paris, March 31, 2026 – Months after receiving CE certification for its Class IIa medical device, neuroClues is already deployed in hospitals across seven European countries. Today, the company announces a €10 million Series A to accelerate one of the fastest clinical rollouts in European neurotech, while concurrently securing additional non-dilutive funding, bringing the total capital raised by neuroClues to €25 million.
The round is led by Teampact Ventures, White Fund and the EIC Fund (European Innovation Council), with participation from existing investors (InvestBW, Leansquare, Wallonie Entreprendre) and the support of Olivier Legrain, Chairman of the Board and CEO of IBA.
The problem: clinical assessment hasn’t changed in 60 years
Neurodegenerative diseases are increasingly prevalent, affecting 1 in 3 people while remaining difficult to diagnose. The number of people affected by Parkinson’s disease worldwide is expected to double to 13 million by 2040. Yet one in five patients is still misdiagnosed and by the time the disease is correctly identified, irreversible brain damage has already occurred leading to a loss of 65% of affected neurons. The reasons: clinicians still rely mostly on clinical observations with no quantitative output such as the “follow my finger” test, and advanced technologies (e.g. imaging) are costly, not widely accessible and often fail to detect abnormalities at early disease stages.
This detection gap impacts quality of life, wastes healthcare resources, and delays treatments.
The solution: objective biomarkers from a 10-minute eye movement exam
neuroClues has built a portable, CE-marked class IIa medical device that extracts neurological biomarkers from eye movements in minutes. A compact device captures high-speed infrared images of each eye while the patient performs simple visual tasks. Proprietary AI algorithms then compute objective, reproducible biomarkers, turning a century of oculomotor research into a practical clinical tool.
Its constraint-free, plug and play design with immediate integration in the clinical workflow bring results in minutes (remote interpretation possible) providing critical clues within the consultation time, not months after.
Today, neuroClues supports clinicians in assessing neurological anomalies objectively, replacing the subjective “follow my finger” test with quantified, reproducible data. Tomorrow, as the platform accumulates clinical data at scale, it aims at supporting the identification of specific pathologies: distinguishing Parkinson’s from atypical parkinsonisms, flagging early signs of Alzheimer’s, detecting concussion-related impairments. Each device deployed makes the platform smarter.
Commercial traction: from CE mark to 7 countries in months
neuroClues obtained its CE certification in January 2025. Within months, over 30 devices were deployed across France, Belgium, Italy, Germany, Switzerland, the Netherlands and the United Kingdom, in university hospitals, private neurology practices and research centers. The company reports growing inbound demand from clinicians who have seen the device at congresses or referenced by peers.
This commercial momentum is backed by landmark clinical partnerships:
- Integration into the Paris Brain Institute’s (ICM) clinical cohorts, including the Iceberg study on Parkinson’s disease
- Selection for the mega-cohort (25,000 participants), which will build the first large-scale normative database of oculomotor biomarkers
- Selected by Bpifrance’s National Prevention Accelerator, accelerating the commercialization through dedicated support.
- Member of an official French presidential delegation to India, unlocking strategic partnerships with leading institutions such as AIIMS.
To match this demand, neuroClues has appointed Bart Stulens, former VP Neuromodulation EMEA at Medtronic, as Chief Commercial Officer. The company is actively scaling its commercial team across Europe, with hires underway in France and distributor agreements signed or under discussions in the EMEA region.
What investors are saying
“Early detection will reshape neurology, and with it, entire health systems. neuroClues is one of the rare companies that has turned decades of academic research into a device that actually works in a doctor’s office, today. That combination of scientific depth and commercial readiness is why we led this round.” — Romain Vidal, Founding Partner, Teampact Ventures
“This Series A validates our technology and our ability to execute. CE certification in five months. First commercial deployments within weeks. A normative database project with 25,000 participants. Today, we give clinicians an objective way to assess neurological anomalies. As our dataset grows, our solution will help them identify specific pathologies earlier and more precisely than ever before. That is where we are headed.” — Antoine Pouppez, CEO, neuroClues
“The speed of clinical adoption since CE certification speaks for itself. neuroClues is solving a problem that every neurologist recognizes, and the market is responding.” — Olivier Legrain, Chairman of the Board, CEO of IBA (Euronext: IBAB — world leader in proton therapy, €600M revenue)
“Objective eye movement evaluation can be considered as an early biomarker for Parkisnon’s disease before some clinical symptoms appear as for example gait and balance disorders or mild cognitive dysfunction. These are invaluable for understanding and monitoring neurological diseases. NeuroClues enables their use in everyday clinical settings, bridging research and real-world care. “– Prof. Marie Vidailhet – Movement Disorder specialist at La Pitié Salpétrière and PI at the Paris Brain Institute
In addition to the new investors, existing shareholders, including Invest.BW, WE and Leansquare, have also participated substantially in this round, reaffirming their continued confidence in neuroClues’ vision, technology, and execution.
A rare opportunity for citizens to co-invest alongside institutional investors
neuroClues has chosen to open a limited tranche up to €1.5M on LITA, the European impact investment platform, allowing citizens and individual investors to participate directly in this round, on the same terms as institutional investors.
LITA added: “NeuroClues addresses a challenge that is both medical and profoundly human, detecting neurological diseases earlier, for a growing number of patients. Beyond the scientific excellence, what convinced us is the company’s ability to turn this research into a concrete, impactful solution for clinicians and patients.”
This window is limited in size and in time. Information and investment access on Lita.
About neuroClues®
neuroClues®, powered by P3Lab, is a European MedTech company founded in 2020 by Antoine Pouppez, Pierre Daye, and Pierre Pouget (CNRS director at Paris Brain Institute). The company develops and commercializes a compact, non-invasive, CE-marked (Class IIa) medical device that records and analyzes eye movements to extract objective & reproducible biomarkers, supporting clinicians in the diagnosis and monitoring of neurological disorders in the clinical practice. More information: https://neuroclues.com & on LinkedIn.
About Teampact Ventures
Teampact Ventures is a European venture capital firm at the intersection of deeptech entrepreneurship and elite sport. With 60+ athlete partners, 250+ private investors, and 25 portfolio companies, Teampact has built a model unlike any other in Europe and is an investor in Alan, BackMarket, Clue, Wandercraft and many others
Teampact first Fund invests in early-stage climate and health startups, and supports them with a proprietary playbook drawn from the world of high-performance sport.
About EIC fund
The European Innovation Council Fund from the European Commission is an agnostic Fund: it invests across all technologies and verticals, and all EU countries and countries associated to Horizon Europe. It provides the investment component of the EIC Accelerator blended finance. The European Investment Bank acts as investment adviser to the EIC Fund.Teampact first Fund invests in early-stage climate and health startups, and supports them with a proprietary playbook drawn from the world of high-performance sport.
The EIC Fund aims to fill a critical financing gap and its main purpose is to support companies in the development and commercialization of disruptive technologies, bridging with and crowding in market players, and further sharing risk by building a large network of capital providers and strategic partners suitable for co-investments and follow-on funding. The Fund pays particular attention to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries.”
About White Fund
WHITE FUND is an investment fund focused on supporting MedTech companies at the pre-market stage through tailored financing solutions and sector expertise. Its shareholder base includes leading private and public investors at both local and national level, such as NOSHAQ, OGEO FUND, SFPI-FPIM, Invest for Jobs and finance&invest.brussels. WHITE FUND also benefits from the support of major healthcare stakeholders, including CHU Liège and Solidaris, giving it access to a strong network of experts and industry connections.
About LeanSquare
LeanSquare (Noshaq Group) is a Liège-based investment fund that invests in entrepreneurs in the digital and new economy sectors. Founded in 2014, LeanSquare is a specialized fund recognized for its impact through its support of innovative projects. Through a relationship built on trust and close collaboration, LeanSquare leverages its capital, expertise, and network to support mature startups in their growth strategies.
About Invest.BW
Invest.BW is a Belgian regional evergreen investment fund managing over €120 million in assets. It invests across all stages of company development, supporting entrepreneurs with a long-term perspective and a strong commitment to sustainable value creation. Its investment strategy focuses on three key areas: breakthrough innovation and emerging technologies, solutions serving health and society, and the digital transformation of traditional industries. More information: www.investbw.be Contact: Pierre de Waha – pdw@investbw.be
About Lita
Lita is a European investment crowdfunding platform dedicated to responsible finance and social and environmental impact. Operating in France and Belgium, it enables both individual and professional investors to directly finance companies developing sustainable, innovative and inclusive solutions. Since its inception, Lita has supported more than 300 projects and mobilized €200 million for the impact economy. In Belgium, Lita supports the growth of local businesses by promoting transparent, citizen-driven financing in service of the ecological and social transition. In 2025, the group reached a new milestone with the launch of Europe’s first citizen co-investment fund, combining citizen savings with professional expertise to amplify the impact of the transition.
Press contacts
- Julien Tesse, Head of Marketing, julien.tesse@p3lab.com